サプリメント4.PDF
|
|
|
- よりお こけい
- 9 years ago
- Views:
Transcription
1 Vol.13,No, Oct.200Vol.13 No. ACE mmHg ACE ACE ACE
2 Vol.13,No.4, L- L- EPA DHA B 2002 a. CSPHP A D E K b. TG DAG DA EPA/DHA EPA DHA n-3 n- EPA DHA n- EPA DHA
3 Vol.13,No, n-6 n- n- n-3 CT CCM CPP K2-7 CCMCPP D3 3
4 Vol.13,No.4, CPP-ACP C 1, E Q10
5 Vol.13,No, n-6 n-3 n-3 n-6 EPA
6 Vol.13,No.4, ED ED 1530mg 1530mg 50200g 6070g L- ED 80% 400mg/ ED L- ED 700mg 1500mg/ DHEA ED ED ED L- QOL
7
8
9 Vol.13,No, No.1 K ACE Ca No.2 H2 A 2 K No.3 L
10 Vol.13,No.4, No Q B1 134 B B D 135 E 136 K CSPHP 138
11 Vol.13,No,2004 c) (6) 36:6.176, c) (7) 36:7.242, c) (8) 36:8.189,2000 A c) (9) 36:9.162, c) (10) 36:10.278, c) (11) 36:11.166, c) (12) 36:12.155, d)(1) 37:1.200, d) (2) 2 37:2.131, a) e) 35:11.168, :3.229, b) f) 35:11.168, :4.172, c) g) (1) 36:1.178, :5.135, c) h) (2) 36:2.192, :6.209, c) I) (3) 36:3.189, :7.190, c) a) (4) 36:4.142, :8.177, c) b) (5) 36:5.139, :9.186,
12 Vol.13,No.4, c) 37:10.278, d) 37:11.171, a) A 37:12.138, b) 38:1.174, c) D 38:2.150, c) (13) 38:3.135, c) (14) 38:4.155, c) (15) 38:5.164, d) (1) 38:6.117, d) (2) 38:7.154, a) (3) 38:8.126, a) (4) 38:9.129, a) (5) 38:10.270, b) 38:11.146, c) B6 38:12.182, d) 39:1.192, a) 39:2.153, ) 422. b) 39:3.125, e) 39:4.139, f) 39:5.168, c) 39:6.134, d) 39:7.212, e) 39:8.154, f) (1) 39:9.138, f) (2) 39:10.135, f) (3) 39:11.140, f) (4) 39:12.217, j) 40:1.131, :9.836, :9.841, :9.846, :9.850,
13 Vol.13,No, :9.856, ) 19:9.861, :4.815, ) 19:9.864,2000 6:8.22, ) 6 19:9.868, :7.119, ) 7 19:9.874, :8.121, ) 8 19:9.878, :9.121, ) 9 19:9.882, :12.117, :9.886, :9.890, OTC 19:9.892, ) 21:7.711, ) 21:8.859, ) 21:8.915, ) (1) 21: , ) (2) 21: , ) (3) 21: , ) 95) 55:5.23,2004 (4) 21: ) 22:2.146, ) 22:5.480, ) 22:6.600, ) Warfarin 116
14 Vol.13,No.4, :6.538,2004 TEL(096) FAX(096)
Vol.9No.22012
6 21 2 21 8 7 118 Vol.9No.22012 6 2 3 1 10 10 1 13 1 13 1320 1956 1961 1977 21 8 1979 1981 1982 2011 2003 20062011 Vol.9No.22012 119 1 23 8 21 1 1 24 20 22 18 8 120 Vol.9No.22012 2 9 1953 2 1979 2 2 1982
取扱説明書
ED-601 ED-501 ED-401 2 3 4 23 14 5 6 18 10 7 1 2 6 3 4 8 9 16 16 16 12 1 2 18 10 2 1 5 12 11 1 2 1 2 12 1 2 13 16 14 3 2 4 1 1 2 16 3 4 18 15 1 2 16 2 3 1 1 2 3 18 17 18 22 19 D A C 20 A B 22 B C D 22
橡サプリメント.PDF
Vol.13,No.1,2004 1 Feb.200Vol.13 No.1 Vol.13,No1,2004 2 70) ph H2 P450 P450 70) Vol.13,No.1,2004 ALDH N- H2 P-450 H2 ADH ADH ADH CYP ADH 200mg/dl ADH P-450CYP CYP CYP 17)18) N- 1 48g ADH 3 Vol.13,No1,2004
2
() () 980-8578 Tel: 022-795-6092 Fax: 022-795-6096 email: 1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 17 46 47 4.1.1
![かんたん操作ガイド[arrows M02]](/thumbs/39/20071242.jpg "かんたん操作ガイド[arrows M02]")
![かんたん操作ガイド[arrows RM02]](/thumbs/39/20475147.jpg "かんたん操作ガイド[arrows RM02]")
![かんたん操作ガイド[arrows M03]](/thumbs/42/22941141.jpg "かんたん操作ガイド[arrows M03]")
木材利用における林野庁施策の動向１
10 1931 10 1050 H21 2,900 45.9% (14%) 253 4.0% 6,321m 3 (100%) 816 12.9% (21%) m 3 2,351 37.2% (41%) 8130 598 1,024m 3 8248% 198m 3 58 7% 1,758m 3 55% 48%+7%=55% 22 519 26 10 4 1 3 Vol53No.4,1998
EL-G37
EL-G37 A A A A A A A A A A A A A A GT F543210A CE CA 4 00. 00 23.80 2 015.6250 77.14286 96. 91. 102. 25. 9. 1 700. 2 720. 2.5 7. 20. 25. 220. 400. 4 096. 4.685 0.084 M 125. M 28. M 85.
橡アロマセラピー症状別処方例.PDF
1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20
障害者職域拡大カリキュラム研究会中間報告書構成案
3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16
Vol.35/No.405 4A pril 2011 Vol.35/No.405 4 April 2011 C O N T E N T S 13 2 04 4 48 6 8 Monthly Digest 10 11 12 13 INFORMATION 14 2010 2011234vol.35 No.4052341 540-0011 2-1-10 Tel.0669467065 Fax.0669460004
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
資料３ 危害や迷惑問題等への対応状況
1 2 3 4 16 12 9 1 5 6 7 8 9 10 11 H16 12 91 10 60 30 13 13 16 12 15 16 14 15 16 (1) (2) (3) 17 18 19 20 () 21 HP http://www.ktr.mlit.go.jp/sinrin/dogrun.htm 22 23 14 5 24 25 11 26 Vol.57No.12004 Vol.56No.122003
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
untitled
...1... 3 1... 3 2... 4 3... 4 4... 5...... 6 1... 6 2... 7 3... 8 4... 9 5... 10... 12 1... 12 2... 13 3... 14 4... 16...... 19 1... 19 2... 20 3... 22 4... 24...... 25... 26 1... 26 2... 26 3... 26......
14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0
2014 6 115 123 総 説 I -VG, 2014 7 24 2014 8 15 -VG, -VG 115
2014 6 107 114 総 説 2014 7 25 2014 8 1 2014 1 20 OTC 107 2014 6 115 123 総 説 I -VG, 2014 7 24 2014 8 15 -VG, -VG 115 2014 6 124 132 原 著 1, 2, 3 4, 5 6 7 8 9 10 3 11 12 1 2 3 4 5 6 7 8 9 10 11 12 2014 3 24
untitled
20073-1- 3 4 5 9 12 14 17-2- 3,700ha 30,000t -3- 1t 70 50 40 C/N -4- 20011228 C/N 13 2001 2cm 1t 60 70 60-5- 70 1t -6- 2003131 ph EC T-C T-N C/N P2O5 K2O CaO MgO HO 2 ms % % % % % % % 8.52 0.64 74.9 44.9
PSCHG001.PS
com plex regional pain syndrom ecrps TPP TPP TPP TPP TEL FA X B M GUS M M CHDF H g Virtual reality PC m onster parents mislead Midnight w alking NHK Skype NHK BS DJ DJ DVD DVD DVD TV BS H H H
, ,279 w
No.482 DEC. 200315 14 1754,406 100.0 2160,279 w 100 90 80 70 60 50 40 30 20 10 28.9 23.8 25.0 19.3 30.4 25.0 29.5 80.7 75.0 75.0 70.5 71.1 69.6 76.2 7 8 9 10 11 12 13 23.2 76.8 14 14 1751,189 100.0 2156,574
平成１４年第８回白根町議会臨時会（１日目）
EPA EPA 10 4 9 10 4 9 10 4 9 10 4 9 NONO () NONO 9 EPA EPA WTO WTO CATV () CATV ( ) () () (2 ) () () CATV A () ()() () () () () 4 2 1 H19,7 1 5 1 H19,4 2 1 1 1 1 1 5 () CATV CATV CATV CATV
untitled
CA 04 1,360 100.8 0.1 83 34,176 7.61 0.40 51,532 1.3 322,736 5.9 05 1,369 100.0 0.8 80 57,269 7.86 0.43 55,001 6.7 311,107 3.6 06 1,370 99.8 0.2 83 48,250 7.73 0.46 56,369 2.5 319,129 2.6 06/ 1-3 99.4
62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -
![62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -](/thumbs/41/22310901.jpg "62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -")
1 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] g/dl A 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - [ ] Point ~ 62 [ ] [ ] [ ] [ ] [ ] [ ] / /
近畿中国四国農業研究センター研究報告 第７号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
取扱説明書 ［F-05E］
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
第３章 焼却灰溶融システムの現状、焼却灰溶融スラグのリサイクルの動向・問題点
18 5 23 450 100~150 1300 1998 10 25 1 1 27 1819 60 3 300t 28.8t 2 62 118t16 12.3 16h 24 3 4 120t 9.6t24h 3 4 100t24h 15t24h 3 4 600t24h 500t24h 5 2 300t24h 75t24h 6 8 80 24h 9.6 24h 4 300t24h 52 24 11